Initial liver involvement in acute GVHD is predictive for nonrelapse mortality

Transplantation

Volumn 88, Issue 9, 2009, Pages 1131-1136

  Robin, Marie ^a   Porcher, Raphael ^b   De Castro, Renato ^a   Fisher, Gustavo ^a   De Latour, Régis Peffault ^a   Ribaud, Patricia ^a   Petropoulou, Anna D ^a   Rocha, Vanderson ^a   Devergie, Agnès ^a   Mary, Jean Yves ^b   Socié, Gérard ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Acute GVHD; Grading system.; Hematopoietic stem cell transplantation; Liver GVHD; Nonrelapse mortality

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; FEMALE; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 72949111356     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181bc2583     Document Type: Article

References (26)

1. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729.
2. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765.
3. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443.
4. Hahn T, McCarthy PL Jr, Zhang MJ, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008; 26: 5728.
5. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295.
6. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855.
7. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.Blood2006; 108: 749.
8. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 1990; 75: 1024.
9. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990; 76: 1464.
10. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825.
11. Saliba RM, de Lima M, Giralt S, et al. Hyperacute GVHD: Risk factors, outcomes, and clinical implications. Blood 2007; 109: 2751.
12. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541.
13. Weisdorf DJ, Hurd D, Carter S, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: A grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003; 9: 512.
14. Cahn JY, Klein JP, Lee SJ, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: A joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005; 106: 1495.
15. Lee KH, Choi SJ, Lee JH, et al. Prognostic factors identifiable atthe time of onset of acute graft-versus-host disease after allogeneic hematopoi-etic cell transplantation. Haematologica 2005; 90: 939.
16. Gooley TA, Rajvanshi P, Schoch HG, et al. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology 2005; 41: 345.
17. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylpred-nisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111: 2470.
18. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977.
19. Sohn SK, Kim DH, Baek JH, et al. Risk-factor analysis for predicting progressive-or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37: 699.
20. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387.
21. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/ 10) in patients with standard-risk hematologic malignancy: A prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695.
22. Ringden O, Pavletic SZ, Anasetti C, et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009; 113: 3110.
23. Arora M, Weisdorf DJ, Spellman SR, et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009; 27: 1644.
24. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic he-matopoietic stem-cell transplantation in adult patients with acute lym-phoblastic leukemia: No difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004; 22: 2816.
25. Finke J, Bethge WA, Schmoor C, et al. A randomized prospective mul-ticenter phase III trial comparing standard GvHD prophylaxis with cyclosporine and methotrexate with additional pretransplant ATG Fre-senius (ATG-F) in allogeneic stem cell transplantation from matched unrelated donors. Blood (ASH Annual Meeting Abstracts) 2008;112:57.
26. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis intransplants from unrelated donors: 2 Randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942.